Pr1 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 51 | 全身性強皮症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-017869-27-DE (EUCTR) | 23/09/2010 | 14/07/2010 | A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis. | A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis. | Diffuse scleroderma MedDRA version: 12.1;Level: LLT;Classification code 10012941;Term: Diffuse scleroderma | Product Name: Terguride Product Code: PR1 INN or Proposed INN: Terguride Other descriptive name: transdihydrolisuride | University Hospital Zurich | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 14 | Germany |